Anpac Bio-Medical Science Company, Ltd., a Chinese developer of early cancer detection technology, raised a Series A funding of several million U.S. dollars.
Shanghai Zhangjiang Science & Technology Investment Corporation (ZJSTIC) made the investment.
Founded in 2008 by by Chief Executive Officer Dr. Chris Yu, Anpac is advancing Cancer Differentiation Analysis (CDA) technology that analyzes non-invasive “Blood Biopsies”.
The company currently collaborates with almost 140 cooperative medical institutions countrywide focused on sample collection, storage, logistics, and sales.
FinSMEs
19/08/2015